CO2022001450A2 - Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina - Google Patents

Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina

Info

Publication number
CO2022001450A2
CO2022001450A2 CONC2022/0001450A CO2022001450A CO2022001450A2 CO 2022001450 A2 CO2022001450 A2 CO 2022001450A2 CO 2022001450 A CO2022001450 A CO 2022001450A CO 2022001450 A2 CO2022001450 A2 CO 2022001450A2
Authority
CO
Colombia
Prior art keywords
salt
compound
kinase inhibitor
forms
crystal forms
Prior art date
Application number
CONC2022/0001450A
Other languages
English (en)
Inventor
Clare Medendorp
Debra Mazaik
Gordon Wilkie
Joshua D Waetzig
Brian Heinrich
Lauren Maceachern
Dominik Siegel
Harald Ohmer
Steven C Johnston
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CO2022001450A2 publication Critical patent/CO2022001450A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen varias formas de sal del Compuesto (I) representadas por la siguiente fórmula estructural y sus correspondientes composiciones farmacéuticas. (I), Formas monocristalinas particulares de succinato del Compuesto (I) 1:1.5, sal de clorhidrato del Compuesto (I) 1:1 y sal de fumarato del Compuesto (I) 1:1 se caracterizan por una variedad de propiedades y medidas físicas. También se describen métodos para preparar formas cristalinas específicas. La presente divulgación también proporciona métodos para tratar o mejorar la fibrodisplasia osificante progresiva en un sujeto.
CONC2022/0001450A 2019-08-13 2022-02-14 Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina CO2022001450A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Publications (1)

Publication Number Publication Date
CO2022001450A2 true CO2022001450A2 (es) 2022-05-31

Family

ID=72193669

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001450A CO2022001450A2 (es) 2019-08-13 2022-02-14 Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina

Country Status (14)

Country Link
US (1) US20220281879A1 (es)
EP (1) EP4013757A1 (es)
JP (1) JP2022544272A (es)
KR (1) KR20220052955A (es)
CN (1) CN114222745A (es)
AU (1) AU2020328534A1 (es)
BR (1) BR112022002597A2 (es)
CA (1) CA3146701A1 (es)
CO (1) CO2022001450A2 (es)
IL (1) IL290482A (es)
JO (1) JOP20220014A1 (es)
MX (1) MX2022001741A (es)
TW (1) TW202120509A (es)
WO (1) WO2021030386A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017250302B2 (en) 2016-04-15 2021-01-21 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase

Also Published As

Publication number Publication date
EP4013757A1 (en) 2022-06-22
IL290482A (en) 2022-04-01
WO2021030386A1 (en) 2021-02-18
AU2020328534A1 (en) 2022-03-17
BR112022002597A2 (pt) 2022-07-05
CN114222745A (zh) 2022-03-22
JOP20220014A1 (ar) 2023-01-30
US20220281879A1 (en) 2022-09-08
TW202120509A (zh) 2021-06-01
CA3146701A1 (en) 2021-02-18
KR20220052955A (ko) 2022-04-28
MX2022001741A (es) 2022-03-11
JP2022544272A (ja) 2022-10-17

Similar Documents

Publication Publication Date Title
MX2018008131A (es) Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma.
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
AR084257A1 (es) Compuestos reguladores del crecimiento de plantas
PH12014501719B1 (en) Pyridone derivatives
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
MX2022015551A (es) Metodos de sintesis para la preparacion de 4-(2-cloro-4-metoxi-5-m etilfenil)-n-[(1s)-2-ciclopropil-1-(3-fluoro-4-metilfenil)etil]-5 -metil-n-prop-2-inil-1,3-tiazol-2-amina.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CY1124795T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια και προφυλαξη λοιμωξεων χειρουργικης θεσης
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4
CY1122468T1 (el) Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου
MX2016017405A (es) Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.
CO2020001861A2 (es) Inhibidores de ror gamma
CO2022001450A2 (es) Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina
BR112018073579A2 (pt) tratamento de transtornos neurológicos
MX2022001861A (es) Procedimiento para la preparacion de 2-(fenilimino)-3-alquil-1,3-t iazolidin-4-onas.
UY38375A (es) Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato
MX2023000938A (es) Proceso de clorantraniliprol mejorado mediante el uso de un intermedio de tipo cristal.
MX2018016387A (es) Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.
BR112023004656A2 (pt) Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
AR086791A1 (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico